PMID- 29668619
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 16
DP  - 2018 Apr
TI  - Gefitinib provides similar effectiveness and improved safety than erlotinib for 
      advanced non-small cell lung cancer: A meta-analysis.
PG  - e0460
LID - 10.1097/MD.0000000000010460 [doi]
LID - e0460
AB  - BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitors 
      gefitinib and erlotinib are effective for advanced non-small cell lung cancer 
      (NSCLC). This meta-analysis compared their effectiveness and safety. METHODS: We 
      searched systematically in PubMed, ScienceDirect, The Cochrane Library, Scopus, 
      Ovid MEDLINE, EMBASE, Web of Science, and Google Scholar for relevant clinical 
      trials regarding gefitinib versus erlotinib for NSCLC. Antitumor effectiveness 
      (overall survival [OS], progression-free survival [PFS], objective response rate 
      [ORR] and disease control rate [DCR]) and adverse effects [AEs]) were assessed. 
      RESULTS: Forty studies comprising 9376 participants were included. The results 
      suggested that gefitinib and erlotinib are effective for advanced NSCLC with 
      comparable PFS (95% confidence intervals [CI]: 0.98-1.11, P = .15), OS (95% CI: 
      0.93-1.19, P = .45), ORR (95% CI: 0.99-1.16, P = .07), and DCR (95% CI: 
      0.92-1.03, P = .35). For erlotinib, dose reduction was significantly more 
      frequent (95% CI: 0.10-0.57, P = .001) as were grade 3 to 5 AEs (95% CI: 
      0.36-0.79, P = .002). In the subgroup analysis, the erlotinib group had a 
      significant higher rate and severity of skin rash, nausea/vomiting, fatigue, and 
      stomatitis. CONCLUSIONS: Gefitinib was proven to be the better choice for 
      advanced NSCLC, with equal antitumor effectiveness and fewer AEs compared with 
      erlotinib. Further large-scale, well-designed randomized controlled trials are 
      warranted to confirm our validation.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Ssecond Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
FAU - Yu, Dongliang
AU  - Yu D
FAU - Xu, Jianjun
AU  - Xu J
FAU - Peng, Jinhua
AU  - Peng J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology
MH  - Comparative Effectiveness Research
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Erlotinib Hydrochloride/*pharmacology
MH  - Gefitinib
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/pathology
MH  - Neoplasm Staging
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Quinazolines/*pharmacology
PMC - PMC5916648
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/04/19 06:00
MHDA- 2018/04/25 06:00
PMCR- 2018/04/20
CRDT- 2018/04/19 06:00
PHST- 2018/04/19 06:00 [entrez]
PHST- 2018/04/19 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2018/04/20 00:00 [pmc-release]
AID - 00005792-201804200-00045 [pii]
AID - MD D-17-06637 [pii]
AID - 10.1097/MD.0000000000010460 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(16):e0460. doi: 10.1097/MD.0000000000010460.